ADVISORY, Sept. 3, 2014 (GLOBE NEWSWIRE) --
BioDelivery Sciences International, Inc. (Nasdaq:BDSI), a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine, will visit the NASDAQ MarketSite in Times Square. BDSI is marking a successful year, which includes the approval of BUNAVAIL™ (buprenorphine and naloxone buccal film) for the maintenance treatment of opioid dependence, which the company will launch using its newly established sales force, the receipt of two positive Phase 3 studies of BEMA Buprenorphine for the treatment of chronic pain, and an encouraging outcome in an interim analysis of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.
In honor of the occasion, Mark Sirgo, President and Chief Executive Officer will ring the Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, September 4, 2014 – 9:15 a.m. to 9:30 a.m. ET
BioDelivery Sciences International, Inc. Media Contact:
Vice President, Marketing and Corporate Development
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/.
A webcast of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About BioDelivery Sciences International, Inc. (Nasdaq:BDSI):
BioDelivery Sciences International, Inc. (Nasdaq:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.
BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.
BDSI's headquarters is located in Raleigh, North Carolina.
For more information visit www.bdsi.com.
About NASDAQ OMX Group
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.
Source:The NASDAQ OMX Group, Inc.